<DOC>
	<DOC>NCT00972426</DOC>
	<brief_summary>The primary objective of the clinical study is to evaluate the efficacy and safety for Mikelan LA eye drops 2% (once per day) of intra-ocular pressure decreased.</brief_summary>
	<brief_title>A Study to Evaluate Efficacy and Safety Effects Using Mikelan® LA Ophthalmic Solution (OS) 2% Versus Timoptol® XE Ophthalmic Solution (OS) 0.5% in Ocular Hypertension Patients</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Latanoprost</mesh_term>
	<mesh_term>Timolol</mesh_term>
	<mesh_term>Carteolol</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>1. Male or females outpatients with primary openangle glaucoma or ocular hypertension; 2. Subjects who have received Latanoprost at least 4 weeks, and in the end of screening period, subject's IntraOcular Pressure is ≧18mmHg (choice of one eyes is possible), or Investigator judges the reduction of IOP is insufficient of individual subject. 3. Aged between ≧ 20 and ≦80 years old when giving informed consent to the study. 1. Hypersensitivity to either oral or topical betablocker therapy or to any ophthalmic solution used in the study; 2. Patients wearing contact lenses; 3. Patients with severe dry eyes; 4. Patients who had ophthalmic surgery including cataract surgery, trabeculotomy or trabeculectomy within three months of study start; 5. Patients who had laser trabeculoplasty within 2 months before starting study; 6. Patients who had corneal contamination, and acute ophthalmic infection, or inflammatory ophthalmic disorder 2 months before starting study; 7. Patients who had herpetic keratitis or corneal ulcer within 2 months before starting study; 8. Patient who are receiving systemic administration of drugs that may have and effect on IOP; 9. Patients who have poorly controlled heart failure, sinus bradycardia, atrioventricular block (1 and 2 grade), or cardiogenic shock; 10. Patients with brochial asthma, bronchospasm or severe chronic obstructive pulmonary disease or a history thereof; 11. Patients with poorly controlled diabetes or diabetic ketoacidosis or metabolic acidosis; 12. Patients with aortic stenosis, Raynaud's syndrome, intermittent claudication, or pheochromocytoma; 13. Patients with myasthenia gravis; 14. Patients with severe hepatic or renal disorder judged by investigator; 15. Patients who have confirmed or potential pregnancy, current lactation, or wish to become pregnant during the study period; 16. Patients who have treatment with any investigational drug when giving informed consent; 17. Patients with significant alcohol, drug or medication abuse as judged by investigator; 18. Patients whom investigator judges as subjects to be inappropriate for the clinical study (e.g., patient with severe complication)</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2011</verification_date>
</DOC>